CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia.
  
  LEARNING OBJECTIVES

  • Review recent therapeutic advances and related FDA authorizations for mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and chronic lymphocytic leukemia (CLL), and use this infor-mation to counsel patients regarding protocol and nonresearch therapy.
  • Consider available Phase III efficacy and safety data with novel targeted agents as first-line therapy for patients with treatment-naïve CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
  • Recall the biologic rationale for and ongoing research evaluating the use of chemotherapy-free combinations in the management of newly diagnosed and progressive CLL and MCL to prepare for the potential introduction of these therapies into practical patient care.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with relapsed/refractory B-cell cancers for whom this approach may be appropriate.
  • Appraise the FDA approval of brentuximab vedotin as a component of first-line therapy for newly diagnosed classical HL, and assess the current and future impact on routine clinical practice.
  • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for MCL, DLBCL, HL and CLL, and where applicable, refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Presenting Faculty Member
  
  Julie M Vose, MD, MBA
  Neumann M and Mildred E Harris Professor
  Chief, Division of Hematology/Oncology
  Nebraska Medical Center
  Omaha, Nebraska
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Verastem Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Epizyme, Janssen Biotech Inc, Kite Pharma Inc, Legend Biotech; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Incyte Corporation, Kite Pharma Inc, Merck, Novartis, Seattle Genetics.
  
  Project Steering Committee Members
  
  Bruce D Cheson, MD
  Lymphoma Consultant
  North Bethesda, Maryland
  
  Advisory Committee: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Dr Reddy’s Laboratories Ltd, Epizyme, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, SymBio Pharmaceuticals Limited, TG Therapeutics Inc; Consulting Agreements: Astellas, Karyopharm Therapeutics, MorphoSys, Parexel International Corporation, SymBio Pharmaceuticals Limited; Contracted Research: AbbVie Inc, Adaptive Biotechnologies, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, TG Therapeutics Inc, Trillium Therapeutics Inc.
  
  Andrew M Evens, DO, MSc
  Associate Director for Clinical Services
  Rutgers Cancer Institute of New Jersey
  Medical Director, Oncology Service Line
  RWJBarnabas Health
  Director, Lymphoma Program, Division of Blood Disorders
  Professor of Medicine
  Rutgers Robert Wood Johnson Medical School
  New Brunswick, New Jersey
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Epizyme, Seattle Genetics, TG Therapeutics Inc, Verastem Inc; Consulting Agreements: American Society for Radiation Oncology, American Society of Hematology; Contracted Research: Leukemia & Lymphoma Society, National Cancer Institute, National Institutes of Health, ORIEN, Tesaro, A GSK Company.
  
  Christopher R Flowers, MD, MS
  Chair, Professor
  Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, OptumRx Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Celgene Corporation, Eastern Cooperative Oncology group, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research; Data and Safety Monitoring Board/Committee: Denovo Biopharma.
  
  Ann S LaCasce, MD, MMSc
  Program Director, Fellowship in Hematology/Oncology
  Associate Professor of Medicine, Harvard Medical School
  Institute Physician
  Lymphoma Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Humanigen Inc; Consulting Agreement: Seattle Genetics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Institutional Research Funding: Celgene Corporation, Forty Seven Inc, Seattle Genetics.
  
  John P Leonard, MD
  Richard T Silver Distinguished Professor of Hematology and Medical Oncology
  Associate Dean for Clinical Research
  Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
  Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, Miltenyi Biotec, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Sutro Biopharma Inc; Contracted Research: Agios Pharmaceuticals Inc, Celgene Corporation; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.
  
  Andrew D Zelenetz, MD, PhD
  Medical Director, Medical Informatics
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Gilead Sciences Inc, MorphoSys; Consulting Agreements: Adaptive Biotechnologies, Amgen Inc, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Novartis, Roche Laboratories Inc, Verastem Inc; Contracted Research: BeiGene, Gilead Sciences Inc, MEI Pharma, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: BeiGene.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Gilead Sciences Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seattle Genetics.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: April 2020
  Expiration date: April 2021